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Efficient communication between neurons is 
essential for all activities ranging from muscle movement 
and motor coordination to higher-order information 
processing and cognitive functions such as learning 
and memory. The majority of fast excitatory synaptic 
transmission in the mammalian central nervous system is 
mediated by the release of glutamates from the presynaptic 
terminal and their binding to the ionotropic AMPA-type 
glutamate receptors (AMPARs) on the postsynaptic 
membrane. Dynamic changes in the trafficking and 
expression of synaptic AMPARs are crucial for synaptic 
plasticity. Therefore, aberrant trafficking of AMPARs 
often leads to deficits in learning and memory [1]. More 
importantly, dysregulation of AMPAR function has 
been implicated in various brain disorders, including 
addiction and, neuropsychiatric and neurodegenerative 
diseases. Elucidating the mechanisms that regulate 
AMPAR trafficking and turnover is therefore critical to 
understanding the fundamental biological process of 
normal brain function, as well as providing insights for 
the identification of potential therapeutic targets. 
Ubiquitination, a reversible post-translational 
modification that is already known to play important roles 
in activity-dependent remodelling of the postsynaptic 
density, synaptic plasticity, learning and memory, has 
recently been shown to directly target AMPAR subunits 
in mammalian central neurons [2, 3]. However, details 
regarding which AMPAR subunits are affected, as well as 
where and how ubiquitination affects receptor functions, 
have proven inconsistent between studies. These 
controversies were addressed in our recent systematic 
study [4]. We found that all AMPAR subunits (GluA1-4) 
undergo activity-dependent ubiquitination when neurons 
are stimulated with the agonist AMPA or the GABA
A
 
receptor antagonist, bicuculline. This process is dependent 
on calcium (Ca2+) influx through the L-type voltage-gated 
Ca2+ channels, which in turn activates the downstream 
effector Ca2+/calmodulin-dependent kinase II (CaMKII). 
How CaMKII influences AMPAR ubiquitination is 
currently unknown, but it is plausible that it directly 
phosphorylates downstream E3 ligases, such as Nedd4-1 
or RNF167, and activates their ubiquitin ligase activity. 
Indeed, such a mechanism has been demonstrated for 
fibroblast growth factor-induced activation of Nedd4-1 
ubiquitin ligase activity through the phosphorylation of 
a tyrosine residue in the HECT domain by the tyrosine 
kinase c-Src [5].
To demonstrate the direct role of ubiquitination on 
AMPAR function, we performed a systematic mapping 
of the sites of ubiquitination on the GluA1 and GluA2 
subunits of AMPARs. We identified Lys-868 and Lys-
870/Lys-882 in the carboxyl-terminal domains as the 
major ubiquitination sites, mutations of which account 
for more than 80% reduction in the levels of GluA1 
and GluA2 ubiquitination, respectively. These Lys-Arg 
mutants allowed us to probe the effects of ubiquitination 
on AMPAR functions, including surface expression, 
endocytosis, intracellular trafficking and turnover, without 
manipulating the expression levels of E3 ligases, which 
target many other protein substrates in neurons. In contrast 
to previous studies [3, 6], we found no evidence of a role 
of ubiquitination in regulating the surface expression of 
AMPARs under basal conditions. This finding is consistent 
with the fact that the levels of AMPAR ubiquitination are 
extremely low in the absence of neuronal activity [2-4]. 
One surprising result emerged from our study is that 
the GluA1 and GluA2 ubiquitin-deficient mutants display 
normal internalisation following AMPA stimulation, which 
contradicts previously reported data [3, 6]. Our findings 
can be explained by the fact that activity-induced (both 
by AMPA and bicuculline) ubiquitination of AMPARs 
is completely abolished by two independent endocytosis 
inhibitors, dynasore and dynole, suggesting that 
ubiquitination of AMPARs must occur post-endocytosis 
[2, 4]. Moreover, we also found that the GluA1 and GluA2 
subunits are modified by K63-linked polyubiquitination 
[4], which predominantly regulates intracellular sorting of 
transmembrane receptors to the late endosome/lysosomal 
compartments. Indeed, our data demonstrated that the 
GluA1 ubiquitin-deficient mutants escape the lysosomal 
degradation pathway, and are instead recycled back to the 
plasma membrane. As a consequence, these mutants are 
more resistant to agonist-induced degradation. 
Although the role of direct ubiquitination of 
AMPAR subunits in receptor endocytosis remains 
controversial, there can be no doubt that the role of 
AMPAR ubiquitination in synaptic plasticity, learning 
and memory is the next outstanding question that needs 
to be addressed. A recent study has implicated the role of 
AMPAR ubiquitination in homeostatic synaptic scaling 
[7]; however whether or not this chemical modification 
is essential for long-term potentiation and/or long-term 
depression is unknown. GluA1 and GluA2 ubiquitin-
deficient knock-in mice could hold the answer. In 
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addition, primary neurons derived from these mice would 
allow us to better study the physiological role of activity-
induced AMPAR ubiquitination without the necessity 
of overexpressing exogenous AMPAR mutants, which 
may potentially be a confounding factor. Given the tight 
association between the ubiquitin-proteasome pathway 
with many neurodegenerative and neuropsychiatric 
disorders, and the fundamental importance of AMPARs in 
normal brain function, we are hopeful that understanding 
the regulatory mechanisms underlying AMPAR function 
through protein ubiquitination will not only shed light 
on the molecular basis of learning and memory, but also 
provide insight into the principles underpinning disease 
aetiology.  
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